摘要:
Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):
摘要:
Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.
摘要:
In the capillary tube 22, the cross section of the outer surface is substantially square, and the cross section of the insertion hole 23 is substantially square. Sides La, Lb of the outer surface have high dimensional accuracy and the insertion hole 23 is made to allow two optical fibers 5, 6 to be inserted while adjoining each other and arranged in order therein. The phases of the outer surface and the insertion hole 23 are relatively offset with each other, so that angles &thgr;a, &thgr;b which the sides 23a, 23b of the insertion hole 23 form with flat surfaces 22a, 22b of the outer surface are acute angles of substantially 45°±0.5°. Consequently, the flat surface 22a becomes substantially parallel to the center line M that connects the centers of the cores 5a, 6a of the two optical fibers 5, 6 inserted in the insertion hole 23, and the flat surface 22b becomes substantially perpendicular to the center line M.
摘要:
Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):
摘要:
Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):
摘要:
A light source using a wavelength conversion member is increased in brightness. A wavelength conversion element 11 includes a plurality of wavelength conversion members 12 bundled together, each containing a dispersion medium and phosphor powder dispersed in the dispersion medium.
摘要:
Provided is a wavelength conversion element that can prevent damage to the wavelength conversion element during the use of the light source and reduce the decrease in intensity of light emitted from the light source equipped with the wavelength conversion element during the use of the light source. The wavelength conversion element 20 includes a wavelength conversion substrate 21 and a reflective layer 24. The wavelength conversion substrate 21, upon incidence of excitation light L0, absorbs part of the excitation light L0 to emit light of different wavelength from the excitation light L0. The reflective layer 24 is disposed on one surface 21b of the wavelength conversion substrate 21. The reflective layer 24 is made of a metal or an alloy.
摘要:
A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): or a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.
摘要:
Heterocyclic compound represented by the formula I wherein represents or the like; R1 represents hydrogen atom, C1-C6 alkyl or benzyloxy; R2 represents methyl or nil; R3 represents hydrogen atom, C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R5 [wherein R5 represents phenyl (which may be substituted with C1-C6 alkyl, halogen atom or cyano)] or thienyl; R4 represents C1-C6 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl or —CH2R6 [wherein R6 represents phenyl (which may be substituted with C1-C6alkyl, halogen atom or cyano), naphtyl or thienyl]; or R3 is coupled with R4.
摘要:
Disclosed is an method of treating cognitive impairment, including administering to a subject in need thereof a combination of a therapeutic agent for neurodegenerative disease and a therapeutically effective amount of a heterocyclic compound represented by the following general formula (I):